Joseph Schwartz
Stock Analyst at Leerink Partners
(4.17)
# 398
Out of 5,182 analysts
155
Total ratings
37.86%
Success rate
21.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $210 → $215 | $135.98 | +58.11% | 5 | Mar 24, 2026 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.35 | +186.94% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $23.99 | +191.79% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.49 | +0.07% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $57.18 | +179.82% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $12.81 | +9.29% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $1.61 | +24.22% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $53.81 | +11.51% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $16.37 | -2.26% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $17.90 | +235.20% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $115 | $54.02 | +112.88% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $38.62 | +127.86% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $20.98 | -28.50% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $19.16 | +4.38% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $7.72 | +55.44% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $26.47 | +5.78% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $40.81 | -1.98% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.80 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $7.50 | +60.00% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.28 | +2,755.10% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $69.22 | -30.66% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $28.71 | -37.30% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $72.23 | -52.93% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $226.66 | -28.09% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.60 | +1,962.50% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.25 | +407.32% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $30.64 | -2.09% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $98.51 | -69.55% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.49 | +705.37% | 2 | Sep 26, 2017 |
Insmed
Mar 24, 2026
Maintains: Outperform
Price Target: $210 → $215
Current: $135.98
Upside: +58.11%
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.35
Upside: +186.94%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $23.99
Upside: +191.79%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.49
Upside: +0.07%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $57.18
Upside: +179.82%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $12.81
Upside: +9.29%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $1.61
Upside: +24.22%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $53.81
Upside: +11.51%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $16.37
Upside: -2.26%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $17.90
Upside: +235.20%
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $54.02
Upside: +112.88%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $38.62
Upside: +127.86%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $20.98
Upside: -28.50%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $19.16
Upside: +4.38%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $7.72
Upside: +55.44%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $26.47
Upside: +5.78%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $40.81
Upside: -1.98%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $4.80
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $7.50
Upside: +60.00%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.28
Upside: +2,755.10%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $69.22
Upside: -30.66%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $28.71
Upside: -37.30%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $72.23
Upside: -52.93%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $226.66
Upside: -28.09%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.60
Upside: +1,962.50%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.25
Upside: +407.32%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $30.64
Upside: -2.09%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $98.51
Upside: -69.55%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.49
Upside: +705.37%